TCZ+GN TR

JRCT ID: jRCT1030200192

Registered date:10/11/2020

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Pancreatic cancer
• Date of first enrollment: 29/05/2019
• Target sample size: 10
• Study type: Observational

Outcome(s)

Primary Outcome

1. Suppresion of IL-6 signaling using a decrease of intratumoral pSTAT3 expression
2. Suppresion of desmoplasia using a decrease of intratumoral alppha-SMA expression
3. Change of tumor-infiltrating lymphocyte

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

1. Partipants for a Phase I study of tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
2. Tumor tissue from the patient was available
3. Written informed consent for participation in the study is obtained at the discretion of the patient.

• Exclude criteria: None

Related Information

• Primary Sponsor: Mitsunaga Shuichi
• Source(s) of Monetary Support: Chugai pharma